Navigation Links
ElutraSep Inc. Announces the Launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia Testing
Date:5/15/2009

ElutraSep, Inc. today announced the commercial launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia testing. www.elutrasep.com/app-Cryptosporidium.asp.

Atlanta, GA (PRWEB) May 15, 2009 -- ElutraSep, Inc. today announced the commercial launch of the Cryptonite™ HV Filter Module for Cryptosporidium and Giardia testing. www.elutrasep.com/app-Cryptosporidium.asp

Cryptonite™ HV is a hollow fiber filtration module designed to capture and concentrate Cryptosporidium and Giardia from non-filtered source and finished water samples. Cryptonite™ HV recently underwent method development for method 1623 at an internationally recognized EPA approved laboratory located in Saint Albans, Vermont.

Testing of the new Cryptonite™ HV filter exceeded the recovery requirements set forth for EPA method 1623 and will now allow laboratories an additional choice for sample concentration. Cryptonite™ offers advantages including a recovery procedure with a total elution volume of less than 50 milliliters, no specialized elution equipment or post filtration required and a start to finish process that can be completed in about two minutes.

"We were always aware of the potential benefits that our technology could bring to the EPA 1623 method but lacked a high volume design that could accommodate turbid source waters. Last year, we began the process of designing a high volume module that would be cost competitive and offer substantial advantages over the competition," said Jason Holt, president and CEO of ElutraSep. " Laboratories will no longer have to conduct tedious elution protocols or have to deal with hundreds of milliliters of elution volumes. Module shakers, wash stations and multiple backwashing steps will be a thing of the past," said Jason. "We believe that the competitive costs of the modules, excellent recoveries and simplified workflows will quickly bring Cryptonite to the front of the pack".

Further information may be obtained by visiting the ElutraSep website www.elutrasep.com or by calling 770-781-5080

ElutraSep, Inc. provides concentration technologies and kits that aid in the detection of microorganisms from liquid samples. Primary product lines utilize inter-capillary capture of organisms via specially designed hollow fiber membranes.

ElutraSep products are typically applied to sample preparation stages of waterborne pathogen assays but are also applied to sterility testing programs in the food, beverage and pharmaceutical industries.

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2419224.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, is ... fully 21 CFR Part 11-compliant email client designed to provide product vigilance departments ...
Breaking Biology Technology:
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):